

This is the peer reviewed version of the following article:

Reliability of calcium-phosphorus (Ca/P) ratio as a new, accurate and inexpensive tool in the diagnosis of some Ca-P disorders / Madeo, B.; De Vincentis, S.; Kara, E.; Vescini, F.; Trenti, T.; Guaraldi, G.; Rochira, Vincenzo. - In: JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. - ISSN 1720-8386. - 42:9(2019), pp. 1041-1049. [10.1007/s40618-019-01025-6]

Terms of use:

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

13/05/2026 22:14

(Article begins on next page)

Journal of Endocrinological Investigation

RELIABILITY OF CALCIUM TO PHOSPHORUS (Ca/P) RATIO AS A NEW, ACCURATE AND INEXPENSIVE TOOL IN THE DIAGNOSIS OF SOME Ca-P DISORDERS

--Manuscript Draft--

Manuscript Number:	JENI-D-18-00768R1
Full Title:	RELIABILITY OF CALCIUM TO PHOSPHORUS (Ca/P) RATIO AS A NEW, ACCURATE AND INEXPENSIVE TOOL IN THE DIAGNOSIS OF SOME Ca-P DISORDERS
Article Type:	Original Article
Funding Information:	
Abstract:	<p>Purpose: The serum calcium/phosphorus (Ca/P) ratio is an accurate tool to differentiate patients with primary hyperparathyroidism (PHPT) from healthy subjects. However, other disorders of the Ca-P metabolism might impair the Ca/P ratio, such as hypophosphatemia (HypoP) not PHPT-related. The aim of this study is to examine the diagnostic value of Ca/P ratio in the diagnosis of PHPT and HypoP not PHPT-related.</p> <p>Methods: Single-center, retrospective, case-control study, including 150 patients with PHPT and 306 patients with HypoP, compared with 150 controls. HypoP patients were enrolled among HIV-infected patients by selecting those with Fanconi-like syndrome due to antiretroviral treatment. Parameters which were measured were serum Ca, P, parathyroid hormone (PTH), 25-OH vitamin D, albumin and creatinine)</p> <p>Results: The Ca/P ratio was significantly higher in PHPT and HypoP patients, compared to controls ($p < 0.0001$). At receiver operator characteristic (ROC) curve analysis, the cut-off of 3.56 (2.75 SI) for Ca/P ratio was able to identify patients with PHPT and HypoP (sensitivity 95%; specificity 93%). Among patients with Ca/P ratio above 3.56, the thresholds of 10.3 mg/dL (2.6 mmol/L) for serum Ca (sensitivity 93%; specificity 98%) and 80.5 pg/mL for PTH (sensitivity 91%; specificity 91%) were defined for the specific diagnosis of PHPT.</p> <p>Conclusions: The Ca/P ratio above 3.56 (2.75 SI) is a highly accurate tool to identify PHPT and HypoP not PHPT-related patients. Thanks to its simplicity, this index can be proposed as a screening and first-line examination in the diagnostic work-up when a disorder of Ca-P metabolism is suspected or should be ruled out.</p>
Corresponding Author:	Bruno Madeo, M.D., PhD Unit of Endocrinology, Department of Medical Specialties, Azienda Ospedaliero-Universitaria di Modena, ospedale Civile di Baggiovara, Modena, Italy Modena, ITALY
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	Unit of Endocrinology, Department of Medical Specialties, Azienda Ospedaliero-Universitaria di Modena, ospedale Civile di Baggiovara, Modena, Italy
Corresponding Author's Secondary Institution:	
First Author:	Bruno Madeo, M.D., PhD
First Author Secondary Information:	
Order of Authors:	Bruno Madeo, M.D., PhD Sara De Vincentis, M.D. Elda Kara, M.D. Fabio Vescini, M.D., Ph.D. Tommaso Trenti, M.D. Giovanni Guaraldi, M.D., Ph.D. Vincenzo Rochira, M.D., Ph.D.

[Click here to view linked References](#)

**RELIABILITY OF CALCIUM TO PHOSPHORUS (Ca/P) RATIO AS A NEW,
ACCURATE AND INEXPENSIVE TOOL IN THE DIAGNOSIS OF SOME Ca-P
DISORDERS**

Bruno Madeo, M.D., Ph.D.¹, Sara De Vincentis, M.D.^{1,2}, Elda Kara, M.D.^{2,3}, Fabio Vescini, M.D.,
Ph.D.³, Tommaso Trenti, M.D.⁴, Giovanni Guaraldi, M.D., Ph.D.⁵, Vincenzo Rochira M.D., Ph.D.^{1,2}

¹Unit of Endocrinology, Department of Medical Specialties, Azienda Ospedaliero-Universitaria of
Modena, Modena, Italy. ²Unit of Endocrinology, Department of Biomedical, Metabolic and Neural
Sciences, University of Modena and Reggio Emilia, Modena, Italy. ³Endocrinology and
Metabolism Unit, University Hospital of Udine, Udine, Italy. ⁴Department of Laboratory Medicine
and Pathological Anatomy, Azienda USL of Modena, Modena, Italy. ⁵Multidisciplinary Metabolic
Clinic, Unit of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy.

Corresponding author:

Bruno Madeo – Unit of Endocrinology, Department of Medical Specialties, Azienda Ospedaliero-
Universitaria di Modena, Ospedale Civile di Baggiovara, Modena, Italy

Via Giardini, 1355 – 41126 MODENA, Italy

Phone: +390593961800 Fax: +390593961335 e-mail: bruno.madeo@unimore.it

ORCID of the Authors:

Bruno Madeo: 0000-0003-2881-982X

Sara De Vincentis: 0000-0002-9582-5683

Fabio Vescini: 0000-0003-1892-9785

Giovanni Guaraldi: 0000-0002-5724-3914

Vincenzo Rochira: 0000-0001-8169-0696

Acknowledgments: None.

Abstract

Purpose: The serum calcium/phosphorus (Ca/P) ratio is an accurate tool to differentiate patients with primary hyperparathyroidism (PHPT) from healthy subjects. However, other disorders of the Ca-P metabolism might impair the Ca/P ratio, such as hypophosphatemia (HypoP) not PHPT-related. The aim of this study is to examine the diagnostic value of Ca/P ratio in the diagnosis of PHPT and HypoP not PHPT-related.

Methods: Single-center, retrospective, case-control study, including 150 patients with PHPT and 306 patients with HypoP, compared with 150 controls. HypoP patients were enrolled among HIV-infected patients by selecting those with Fanconi-like syndrome due to antiretroviral treatment. Parameters which were measured were serum Ca, P, parathyroid hormone (PTH), 25-OH vitamin D, albumin and creatinine)

Results: The Ca/P ratio was significantly higher in PHPT and HypoP patients, compared to controls ($p < 0.0001$). At receiver operator characteristic (ROC) curve analysis, the cut-off of 3.56 (2.75 SI) for Ca/P ratio was able to identify patients with PHPT and HypoP (sensitivity 95%; specificity 93%). Among patients with Ca/P ratio above 3.56, the thresholds of 10.3 mg/dL (2.6 mmol/L) for serum Ca (sensitivity 93%; specificity 98%) and 80.5 pg/mL for PTH (sensitivity 91%; specificity 91%) were defined for the specific diagnosis of PHPT.

Conclusions: The Ca/P ratio above 3.56 (2.75 SI) is a highly accurate tool to identify PHPT and HypoP not PHPT-related patients. Thanks to its simplicity, this index can be proposed as a screening and first-line examination in the diagnostic work-up when a disorder of Ca-P metabolism is suspected or should be ruled out.

Key words: Calcium-Phosphorus metabolism, hyperparathyroidism, hypophosphatemia, screening

Introduction

The calcium to phosphorus (Ca/P) ratio has been recently proposed for the first time as a simple and accurate tool to discriminate patients with primary hyperparathyroidism (PHPT) from healthy subjects. The reliability of this index is based on the fact that Ca and P homeostasis are closely regulated and their serum concentration is inversely correlated [1-3]. The diagnosis of PHPT is traditionally based on increased serum Ca and intact parathyroid hormone (PTH) levels [4, 5], in association with slight or mild hypophosphatemia (HypoP) [5, 6]. However, the biochemical profile of PHPT is not always so evident, making the diagnosis of PHPT challenging. For this reason, the serum Ca/P ratio could help in the diagnostic workup of PHPT, especially in asymptomatic or normocalcemic patients [3].

Nevertheless, although PHPT is the most common cause of hypercalcemia [6, 7], other disorders of the Ca-P metabolism might impair the Ca/P ratio. For example, a condition of HypoP not due to PHPT should be considered.

HypoP is a rare disease [8] that may occur by several mechanisms [9], including internal redistribution (eg, malnutrition, sepsis) or increased urinary excretion (eg, X-linked hypophosphatemic rickets, Fanconi syndrome) [10, 11]. A phosphate wasting disorder is also frequently observed in patients with Human Immunodeficiency Virus (HIV)-infection with ongoing combination antiretroviral therapy (cART) [12, 13]. In particular, among antiretroviral drugs, the use of tenofovir has been correlated with mild to severe hypophosphatemia, through a renal tubular dysfunction and chronic increased phosphaturia, resulting in a Fanconi-like syndrome [12-14].

In our previous study, the lack of a group of patients with HypoP limited the validation of serum Ca/P ratio for the differential diagnosis between PHPT and other causes of altered Ca/P ratio.[3]. For example, tenofovir-related hypophosphatemia represents a mono-factorial hypophosphatemia, making HIV-infected patients with HypoP a uniform cohort to compare with PHPT patients.

1 The aim of the study is to evaluate the accuracy and diagnostic value of Ca/P in the diagnosis
2 of PHPT and HypoP related to Fanconi-like syndrome and to investigate if this index can be used
3
4 for differential diagnosis.
5
6
7
8

9 **Subjects and Methods**

10 *Study Design*

11 A single-centre, retrospective, case-control study was carried out.
12
13

14 The group of cases with ascertained diseases of Ca-P metabolism was composed by two
15 subgroups: patients with a certain diagnosis of PHPT and HIV-infected patients with HypoP.
16
17 Controls consisted of subjects without any disorder of Ca-P metabolism. This trial was registered in
18
19 ClinicalTrials.gov (Identifier: NCT03603444).
20
21
22
23
24
25
26
27

28 *Subjects*

29 A total of 150 patients followed at the Unit of Endocrinology of Modena with a diagnosis of
30
31 PHPT from 2005 to January 2018 were included in the first case group (Table 1). For the other
32
33 group of cases, 306 subjects with a certain diagnosis of drug-induced HypoP with reduced serum P
34
35 according to the lower limit of the normal range of our laboratory (2.5 mg/dL), but normal serum
36
37 Ca, were enrolled among HIV-infected patients on cART treatment from the large Modena cohort
38
39 that belongs to Modena HIV Metabolic Clinic (MHMC), from 2004 to 2017. In this tertiary care
40
41 teaching Hospital in Northern Italy, all individuals are screened by a multidisciplinary team for
42
43 immune-metabolic disorders, antiretroviral-associated toxicities, HIV-associated non-infectious
44
45 endocrine co-morbidities, geriatric syndromes and disabilities [15]. In particular, Ca, P, PTH and
46
47 vitamin D are routinely checked at baseline in order to exclude Ca metabolism disorders related to
48
49 osteoporosis or drug toxicity. By considering the low prevalence of hypophosphatemia in the
50
51 general population and the availability of a easily-accessible large database, we chose to investigate
52
53 the tenofovir-related hypophosphatemia since it allowed us to select quickly a large sample of
54
55
56
57
58
59
60
61
62
63
64
65

1 patients with hypophosphatemia and to have a homogeneous mono-factorial disease, such as
2 tenofovir-related hypophosphatemia, to compare with PHPT. Tenofovir-related hypophosphatemia,
3
4 however, should be considered highly representative of all other types of hypophosphatemia at least
5
6 for the aim of this study since it leads to the same changes in serum such as other types of
7
8 hypophosphatemia.
9
10

11 As a control group, we retrospectively selected 150 patients who attended the Unit of
12
13 Endocrinology of Modena in the same time period, presenting serum PTH, Ca and P within the
14
15 normal range. In particular, 43 (28.7%) were healthy subjects, 30 (20.0%) were male hypogonadal
16
17 patients with documented normal serum testosterone during testosterone replacement therapy, 27
18
19 (18.0%) had a pituitary disease (non-functioning pituitary adenoma or empty sella with normal
20
21 pituitary function), 17 (11.3%) had a non-functioning adrenocortical adenoma, 33 (22.0%) had a
22
23 thyroid disorder (history of thyroidectomy, chronic thyroiditis or nodular goiter).
24
25
26
27

28 The following parameters were needed for the inclusion in each group: age, gender, serum Ca,
29
30 P, PTH, 25-OH vitamin D and creatinine (Table 1).
31
32
33

34 Exclusion criteria for both cases and controls were: age younger than 18 or older than 90 years;
35
36 severe renal and liver diseases (i.e. glomerular filtration rate (GFR) <30 mL/min);
37
38 hyperparathyroidism secondary to Vitamin D deficiency; history of parathyroidectomy, even if the
39
40 parathyroid disorder was considered in remission; active metabolic bone disease (e.g. Paget's
41
42 disease of the bone, osteomalacia, rickets, etc); any type of cancer; malnutrition; severe obesity
43
44 (BMI > 40 kg/m²); a history of gastrointestinal malabsorption; sarcoidosis; hypercortisolism,
45
46 (BMI > 40 kg/m²); a history of gastrointestinal malabsorption; sarcoidosis; hypercortisolism,
47
48 diabetes insipidus, hyperthyroidism, hypoparathyroidism and pseudohypoparathyroidism; familial
49
50 hypocalciuric hypercalcemia (FHH); treatment with steroids, calcium and/or active forms of
51
52 vitamin D (calcitriol, ergocalciferol, etc), thiazides, phosphate binders, lithium, cinacalcet,
53
54 bisphosphonates, and denosumab.
55
56
57

58 The characteristics of patients and controls are summarized in Table 1.
59
60
61
62
63
64
65

Laboratory analyses

1
2 Serum Ca and P were detected using Beckman Coulter AU 680 (Beckman Coulter Italy,
3
4 Cassina de' Pecchi, Milan, Italy) device by the colorimetric photometric methods based on
5
6 Arsenazo III and molybdate, respectively. For both sexes, the normal reference ranges for serum Ca
7
8 and P were 8.5-10.5 mg/dL and 2.5-5.1 mg/dL, respectively.
9
10

11 Serum Intact PTH was determined by two house-different chemiluminescence assays: a
12
13 DiaSorin Liaison (DiaSorin S.p.A., Saluggia, Vercelli, Italy) from January 2005 to June 2010 and a
14
15 Beckman Coulter UniCel DxI 600 Synchron Access (Beckman Coulter Italy, Cassina de' Pecchi,
16
17 Milan, Italy) from June 2010 to January 2018. The normal reference range for serum PTH was 15-
18
19 88 ng/L, with an intra-assay variability coefficient of 5%.
20
21

22 Serum 25OH-Vitamin D was measured by chemiluminescence with the LIASON® XL
23
24 1,25OH-Vitamin D assay (DiaSorin, Stillwater, MN). Normal reference range is 30-100 ng/mL and
25
26 the intra- and inter-assay variability coefficient was <10%.
27
28

29 Plasma albumin-adjusted corrected Ca (corrected Ca) was calculated to account for falsely low
30
31 serum calcium values due to hypoalbuminemia. We applied the following formula to all patients for
32
33 which serum albumin was available in the record chart: corrected total calcium (mg/dL) = total
34
35 serum calcium (mg/dL) + 0.8*[4 – serum albumin (g/L)] [5, 16].
36
37
38
39
40
41
42

Ethics

43
44
45
46 Consent has been obtained from each patient or subject after full explanation of the purpose
47
48 and nature of all procedures used.
49

50
51 The Institutional Review Board of Azienda Ospedaliero-Universitaria of Modena approved the
52
53 study (Protocol n. 0032443/15).
54
55
56
57

Statistical analysis

1 All data are shown as median and minimum-maximum. Comparisons among groups were
2 performed by the nonparametric Mann-Whitney *U* and Kruskal-Wallis tests, followed by the
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

The diagnostic accuracy of Ca/P was investigated using receiver operator characteristic (ROC) curve in order to define cut-off points that better identify affected patients according to their biochemical profile. ROC cut-offs were calculated by the Youden's index through the identification of the best pair of sensitivity and specificity.

Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy were evaluated.

Statistical analyses were performed using the Statistical Package for the Social Sciences' (SPSS) software for Windows (version 25.0; SPSS Inc, Chicago, IL). For all comparisons, $p < 0.05$ was considered statistically significant.

Results

Age, sex and biochemical parameters of each group are summarized in Table 1.

Serum Ca was significantly higher in PHPT patients than either HypoP patients or controls ($p < 0.0001$) (Table 1). As expected, even serum PTH was higher in PHPT group than others ($p < 0.0001$) (Table 1).

Conversely, serum P was significantly lower in HypoP patients than PHPT patients and controls ($p < 0.0001$) (Table 1).

The Ca/P ratio was significantly lower in controls compared to both PHPT ($p < 0.0001$) and HypoP patients ($p < 0.0001$), but it did not significantly differ among HypoP and PHPT groups ($p = 0.075$) (Table 1).

Serum albumin, necessary for the calculation of corrected Ca, was available in 124 PHPT patients (79.3%), 299 HypoP patients (97.7%) and 119 controls (79.3%) (Table 1). Similarly, to

1 serum Ca, even serum corrected Ca was higher in PHPT patients than controls ($p<0.0001$) and
2 HypoP patients ($p<0.0001$) (Table 1).
3

4 Vitamin D did not differ between controls and PHPT patients, but it was significantly higher in
5 HypoP group ($p<0.0001$) (Table 1). In particular, 57 controls (38.3%), 69 PHPT patients (50.7%)
6 and 70 HypoP patients (23.9%) had vitamin D deficiency with serum levels of 25-OH vitamin D
7 below 20 ng/mL.
8
9

10 Considering renal function, serum creatinine did not differ comparing controls to PHPT group,
11 but it was higher in HypoP group (<0.0001) (Table1). The GFR was between 30 and 60 mL/min in
12 8 controls (6.2%), 19 PHPT (12.8% and 15 HypoP (4.9%) patients; all other subjects had a GFR
13 greater than 60 mL/min.
14

15 In addition, HIV-infected patients and controls were mostly male patients, while PHPT were
16 predominantly female (Table 1). HIV-infected patients were significantly younger than PHPT
17 patients and controls ($p<0.0001$) (Table 1).
18
19

20 Among PHPT patients, 38 (25.3%) were normocalcemic, while 112 (74.7%) had serum Ca
21 above the normal range.
22
23

24 Table 2 shows the diagnostic values of conventional parameters used to define a condition of
25 altered Ca-P metabolism, including either PHPT or HypoP. The Ca/P threshold of 3.56 (2.75 SI),
26 obtained by ROC curve analysis, was identified as the best pair of sensitivity (93%) and specificity
27 (92.7%) (Table 2, Figure 1a). In particular, by using the Ca/P ratio with a cut-off of 3.56, 424 out of
28 the 456 HypoP and PHPT patients were correctly identified as patients with Ca-P metabolism
29 disorder, while only 11 out of the 150 controls were falsely classified as having a disorder of Ca-P
30 metabolism (Figure 2). When serum albumin was available, the use of serum corrected Ca/P ratio
31 with a cut-off of 3.47 (2.68 SI) had a diagnostic power (sensitivity 93.4%, specificity 93.2%)
32 similar to that of Ca/P (Table 2). Accordingly, PPV, NPV and accuracy of both Ca/P and corrected
33 Ca/P were the best ones compared to the diagnostic values of PTH, serum Ca, corrected Ca and P
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 (Table 2). As expected, either serum Ca or PTH that were used as inclusion criteria for controls, act
2 as confounders for the diagnostic performance (Table 2).
3

4 The combined use of Ca/P and serum Ca (which was considered positive when at least one of
5 the two biochemical parameters was above the respective cut-offs) had the best sensitivity (95.2%)
6 and specificity (92.7%) together with the best PPV, NPV and accuracy, all these parameters
7 performing better than Ca/P alone to identify patients with impaired Ca-P metabolism (Table 2).
8
9

10 The statistical analysis performed by considering only normocalcemic patients from the PHPT
11 cohort confirmed that 3.56 of Ca/P ratio was reliable to identify the cases (normocalcemic PHPT
12 and HypoP) from controls. However, no valid cut-off was found to differentiate normocalcemic
13 PHPT from HypoP patients.
14

15 Similarly, ROC curve analysis performed for patients with sufficient vitamin D and for patients
16 with vitamin D insufficiency showed the same cut-off (Ca/P 3.56) with similar specificity and
17 sensitivity. The same results were obtained comparing the ROC curves of patients with GFR 30-60
18 ml/min with those with GFR >60 ml/min.
19
20

21 Overall, by considering all patients with Ca-P metabolism disorder (PHPT and HypoP) with
22 Ca/P above 3.56, the use of serum Ca and/or serum PTH alone had the best diagnostic value in
23 discriminating PHPT from HypoP patients, as expected (Table 3, Figure 1b). In particular, the
24 thresholds of 10.3 mg/dL (2.6 mmol/L) for serum Ca (sensitivity 92.6%; specificity 98.7%) and of
25 80.5 pg/mL for PTH (sensitivity 90.9%; specificity 90.9%) were defined for the specific diagnosis
26 of PHPT (Table 3, Figure 1b). Similarly, for those patients whose albumin was measured, corrected
27 Ca had very high diagnostic power for the threshold of 9.85 mg/dL (sensitivity 100%, specificity
28 99.7%) (Table 3).
29
30

31 On the other hand, it was not possible to identify any useful cut-off for serum P in order to
32 discriminate PHPT from HypoP (Table 3).
33
34

35 Discussion

1 This study shows that serum Ca/P ratio has a great diagnostic power in identifying patients
2 with PHPT and patients with HypoP not PHPT-related. In particular, a Ca/P value above 3.56 (with
3 Ca and P measured in mg/dL) results to be an accurate, highly sensitive and highly specific tool to
4 define a condition of impaired Ca-P metabolism due to PHPT or HypoP not PHPT-related. More
5 importantly, both sensitivity and accuracy further increases if serum Ca and Ca/P are used in
6 combination (Table 2).
7
8
9
10
11
12
13

14 This is in line with our previous results, since the accuracy of Ca/P to diagnose or rule out a
15 condition of PHPT remained unaltered after adding patients with HypoP [3]. In addition to PHPT
16 group, the inclusion of HypoP patients allowed us to investigate the accuracy of Ca/P in the
17 differential diagnosis of other Ca-P metabolism disorders, such as HypoP not PHPT-related.
18 Unfortunately, we did not find any valid cut-off of Ca/P ratio useful to discriminate patients with
19 HypoP not PHPT-related from those with PHPT, either normocalcemic or hypercalcemic. Thus, up
20 to now, we can conclude that this index is not useful to differentiate PHPT from HypoP among
21 disorders of Ca-P metabolism.
22
23
24
25
26
27
28
29
30
31
32
33

34 At the same time, our results show that the use of serum Ca alone with a cut-off of 10.3 mg/dL
35 allows identifying patients with PHPT among all patients with Ca/P ratio above 3.56. In this
36 perspective, we recommend measuring serum Ca and P as first step in the screening of Ca-P
37 metabolism disorders (Figure 3). Serum Ca allows to define a condition of PHPT or HypoP due to
38 other causes, once the calculated Ca/P ratio is found above 3.56 (Figure 3). Accordingly, PHPT or
39 HypoP not related to PHPT should be highly considered when serum Ca is above or below 10.3
40 mg/dL, respectively (Figure 3). As a consequence and in contrast to the current guidelines on the
41 management of PHPT [4], not only Ca and PTH, but also P, are useful for identifying patients with
42 PHPT. For this reason, we recommend including serum P in the clinical work-up for the diagnosis
43 of PHPT. On the other hand, this study further demonstrates that serum P alone is unreliable in the
44 diagnosis of PHPT, in accordance with all previous studies that evaluated this parameter alone and
45 never in combination with serum Ca [17-20]. In the literature, there is no agreement about the use
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 of serum P as first-step examination in the diagnostic work-up of bone mineral diseases. Current
2 clinical guidelines do not actually recommend to measure serum P for the diagnosis of PHPT [4]
3 and for the management of nephrolithiasis [21-23]. On the contrary, serum P is included among first
4 tier investigations for urolithiasis by a recent consensus statement [24] and for the management of
5 osteoporosis by several Societies [25-30]. Again, we recommend measuring serum P together with
6 serum total Ca allowing to calculate Ca/P as screening of Ca-P metabolism disorders, especially in
7 the above-mentioned clinical settings, while serum PTH is not strictly needed as first-line
8 biochemical investigation to rule out PHPT (Figure 3).
9

10
11
12
13
14
15
16
17
18
19 In the clinical real-life, the measurement of serum Ca and serum P may be sufficient as first
20 investigation for the diagnosis of PHPT that is one of the most frequent disorders of Ca-P
21 metabolism [6, 7]. In addition to their worldwide availability and extreme simplicity, the use of
22 serum Ca and P may avoid further outgoings and clinical complications due to a delayed diagnosis
23 of PHPT, occurring in a relevant percentage (about 40%) of cases [4, 31-34].
24
25
26
27
28
29
30

31 The retrospective design represents the main limit of this study, but it assures a correct
32 assignment to control or case (either PHPT or HypoP) groups. Another limit is represented by the
33 lack of age- and gender-matching between patients and controls. Furthermore, vitamin D
34 insufficiency and slight impairment of GFR seem to not influence the accuracy of Ca/P index.
35
36
37
38
39
40

41 In conclusion, this study further validates the serum Ca/P ratio above 3.56 (2.75 SI) as a highly
42 accurate tool to identify patients with PHPT and HypoP not PHPT-related. Thanks to its
43 extraordinary simplicity, together with the favourable cost-effectiveness, this index can be proposed
44 as a screening and first-line examination in the diagnostic work-up when a disorder of Ca-P
45 metabolism is suspected or should be ruled out, such as in patients with osteoporosis or
46 nephrolithiasis. Moreover, both sensitivity and accuracy further increases when Ca/P ratio is taken
47 in combination with serum total Ca. The use of a simple index, such as Ca/P, might be particularly
48 useful especially in laboratory/medical settings relying on limited resource, in which second- or
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

third-generation assays for PTH are not available. Furthermore, the timely diagnosis of PHPT is useful for preventing the development of PHPT-related comorbidities.

Finally, prospective and multi-centre studies on larger sample size will be needed to confirm and validate our findings for PHPT and HypoP patients. Moreover, future studies may be performed to extent the application of Ca/P to diagnose other disorders of Ca-P metabolism, such as hypoparathyroidism, pseudohypoparathyroidism and secondary hyperparathyroidism

Declaration of interest

The authors declare that they have no conflict of interest.

Funding

This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Authors contributions

B. Madeo is the Principal Investigator and conceived the study, analysed the data, provided data interpretation and wrote the manuscript. S. De Vincentis collected and analyzed the data, and wrote the manuscript. E. Kara collected clinical and biochemical data. F. Vescini contributed to conceive the study. T. Trenti provided data about laboratory assays. G. Guaraldi provided clinical and biochemical data about HypoP patients. V. Rochira conceived the study, analysed the data, provided data interpretation and wrote the manuscript. All authors approved the final version of the manuscript and fully contributed to its final version.

References

1. Shaker JL, Deftos L (2000) Calcium and Phosphate Homeostasis. In De Groot LJ, Chrousos G, Dungan K, et al. (eds) Endotext. MDText.com, Inc., South Dartmouth (MA)
2. Peacock M (2010) Calcium metabolism in health and disease. Clin J Am Soc Nephrol 5 Suppl 1:S23-30
3. Madeo B, Kara E, Cioni K, Vezzani S, Trenti T, Santi D, Simoni M, Rochira V (2018) Serum Calcium to Phosphorous (Ca/P) Ratio Is a Simple, Inexpensive, and Accurate Tool in the Diagnosis of Primary Hyperparathyroidism. JBMR Plus 2:109-117
4. Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, Potts JT, Jr. (2014) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 99:3561-3569
5. Marcocci C, Cetani F (2011) Clinical practice. Primary hyperparathyroidism. The New England journal of medicine 365:2389-2397
6. Fraser WD (2009) Hyperparathyroidism. Lancet 374:145-158
7. Griebeler ML, Kearns AE, Ryu E, Hathcock MA, Melton LJ, 3rd, Wermers RA (2015) Secular trends in the incidence of primary hyperparathyroidism over five decades (1965-2010). Bone 73:1-7
8. Christov M, Juppner H (2018) Phosphate homeostasis disorders. Best Pract Res Clin Endocrinol Metab 32:685-706
9. Boland JM, Tebben PJ, Folpe AL (2018) Phosphaturic mesenchymal tumors: what an endocrinologist should know. J Endocrinol Invest 41:1173-1184
10. Gaasbeek A, Meinders AE (2005) Hypophosphatemia: an update on its etiology and treatment. Am J Med 118:1094-1101
11. Marcucci G, Masi L, Ferrari S, Haffner D, Javaid MK, Kamenicky P, Reginster JY, Rizzoli R, Brandi ML (2018) Phosphate wasting disorders in adults. Osteoporos Int

12. Casado JL, Santiuste C, Vazquez M, Banon S, Rosillo M, Gomez A, Perez-Elias MJ, Caballero C, Rey JM, Moreno S (2016) Bone mineral density decline according to renal tubular dysfunction and phosphaturia in tenofovir-exposed HIV-infected patients. *Aids* 30:1423-1431
13. Bagnis CI, Karie S, Deray G, Essig M (2009) Hypophosphataemia: an easy strategy for diagnosis and treatment in HIV patients. *Antivir Ther* 14:481-488
14. Labarga P, Barreiro P, Martin-Carbonero L, et al. (2009) Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. *Aids* 23:689-696
15. Rochira V, Zirilli L, Orlando G, Santi D, Brigante G, Diazz C, Carli F, Carani C, Guaraldi G (2011) Premature decline of serum total testosterone in HIV-infected men in the HAART-era. *PLoS One* 6:e28512
16. Smith JD, Wilson S, Schneider HG (2018) Misclassification of Calcium Status Based on Albumin-Adjusted Calcium: Studies in a Tertiary Hospital Setting. *Clin Chem* 64:1713-1722
17. Boyd JC, Ladenson JH (1984) Value of laboratory tests in the differential diagnosis of hypercalcemia. *Am J Med* 77:863-872
18. Avioli LV (1968) The diagnosis of primary hyperparathyroidism. *Med Clin North Am* 52:451-462
19. Strott CA, Nugent CA (1968) Laboratory tests in the diagnosis of hyperparathyroidism in hypercalcemic patients. *Ann Intern Med* 68:188-202
20. Reiss E (1970) Primary hyperparathyroidism: a simplified approach to diagnosis. *Med Clin North Am* 54:131-139
21. Turk C, Petrik A, Sarica K, Seitz C, Skolarikos A, Straub M, Knoll T (2016) EAU Guidelines on Diagnosis and Conservative Management of Urolithiasis. *Eur Urol* 69:468-474
22. Pearle MS, Goldfarb DS, Assimos DG, et al. (2014) Medical management of kidney stones: AUA guideline. *J Urol* 192:316-324
23. Morgan MS, Pearle MS (2016) Medical management of renal stones. *Bmj* 352:i52

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
24. Gambaro G, Croppi E, Coe F, et al. (2016) Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement. *J Nephrol* 29:715-734
25. Camacho PM, Petak SM, Binkley N, et al. (2016) AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016. *Endocr Pract* 22:1-42
26. Rossini M, Adami S, Bertoldo F, et al. (2016) Guidelines for the diagnosis, prevention and management of osteoporosis. *Reumatismo* 68:1-39
27. Nuti R, Brandi ML, Checchia G, et al. (2018) Guidelines for the management of osteoporosis and fragility fractures. *Intern Emerg Med*
28. Rochira V, Antonio L, Vanderschueren D (2018) EAA clinical guideline on management of bone health in the andrological outpatient clinic. *Andrology* 6:272-285
29. Vescini F, Attanasio R, Balestrieri A, et al. (2016) Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis. *J Endocrinol Invest* 39:807-834
30. Compston J, Bowring C, Cooper A, et al. (2013) Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. *Maturitas* 75:392-396
31. Chen G, Xue Y, Zhang Q, et al. (2015) Is Normocalcemic Primary Hyperparathyroidism Harmful or Harmless? *J Clin Endocrinol Metab* 100:2420-2424
32. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP (1999) A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. *N Engl J Med* 341:1249-1255

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

33. Lundstam K, Heck A, Mollerup C, et al. (2015) Effects of parathyroidectomy versus observation on the development of vertebral fractures in mild primary hyperparathyroidism. J Clin Endocrinol Metab 100:1359-1367

34. Eastell R, Brandi ML, Costa AG, D'Amour P, Shoback DM, Thakker RV (2014) Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 99:3570-3579

Legends

Figure 1a. ROC curve analysis for Ca/P together with cut-off, sensitivity, specificity, area under the curve, standard error, and 95% confidence interval values. **Figure 1b.** ROC curve analysis for Ca and PTH among PHPT and HypoP patients with Ca/P above 3.56 (2.75 SI), together with cut-off, sensitivity, specificity, area under the curve, standard error, and 95% confidence interval values.

[footnote to Figure 1]: Ca/P: serum calcium/phosphorus ratio (Ca and P measured in mg/dL); SI: International System of Units (Ca and P are measured in mmol/L); AUC: Area Under the Curve; SE: Standard Error; CI: Confidence Interval. Ca: serum calcium (black line in Figure 1b); PTH: serum parathyroid hormone (grey line in Figure 1b); PHPT: primary hyperparathyroidism; HypoP: hypophosphemia.

Figure 2. Distribution of serum Ca/P ratio and serum Ca of all patients according to the thresholds of 3.56 for Ca/P ratio, to discriminate controls from PHPT and HypoP, and of 10.3 mg/dL for serum Ca, to discriminate PHPT from HypoP in patients with Ca/P > 3.56.

[footnote to Figure 2]: Ca/P: serum calcium to phosphorus ratio; Ca: serum calcium (Ca and P measured in mg/dL); controls (marker: black diamonds); PHPT: primary hyperparathyroidism (marker: light grey circles); HypoP: hypophosphatemia (marker: dark grey triangles).

Figure 3. Usefulness of Ca/P in the diagnostic flow-chart for the screening and diagnosis of Ca-P metabolism disorders.

[footnote to Figure 3]: Ca: serum calcium; Ca/P: serum calcium/phosphorus ratio (Ca and P measured in mg/dL); PHPT: primary hyperparathyroidism; HypoP: hypophosphatemia; SI: International System of Units (Ca and P are measured in mmol/L)

Table 1. Age, biochemical and hormonal differences between patients with PHPT, HypoP and controls. Measurements are expressed as median (minimum-maximum).

	Normal range	PHPT n=150	HypoP n=306	Controls n=150	p-value
Sex					
Females	-	113 (75.3%)	54 (17.6%)	64 (42.7%)	-
Males	-	37 (24.7%)	252 (82.4%)	86 (57.3%)	-
Age (yrs)	-	63.5 (23.7-90.0)*°	48.5 (27.4-77.0)^	57.1 (19.8-89.0)	<0.0001
Serum Ca (mg/dL)	8.5-10.5	10.9 (9.3-18.0)*°	9.4 (8.5-10.5)	9.4 (8.7-10.5)	<0.0001
Serum P (mg/dL)	2.5-5.1	2.5 (1.5-3.9)*°	2.3 (1.5-2.5)^	3.6 (2.5-4.9)	<0.0001
Ca/P	-	4.36 (2.38-12.00)*	4.07 (3.46-6.20)^	2.69 (2.02-4.08)	<0.0001
Serum PTH (pg/mL)	15-88	130.6 (49.9-1748.0)*°	42.4 (6.2-308.2)#	34.0 (14.0-88.0)	<0.0001
Serum 25-OH vitamin D (ng/mL)	30-100	19.7 (3.0-59.2)°	29.1 (4.0-100.0)^	22.7 (4.0-74.8)	<0.0001
Serum creatinine (mg/dL)	0.50-1.20	0.80 (0.50-2.58)°	0.91 (0.53-2.35)^	0.80 (0.55-1.70)	<0.0001
Serum albumin (g/dL)**	3.5-5.0	4.1 (2.6-5.0)§°	4.6 (3.4-5.6)^	4.3 (2.7-4.9)	<0.0001
Serum corrected Ca (mg/dL)**	-	10.9 (9.3-18.2)*°	8.8 (7.9-9.9)^	9.2 (8.6-10.7)	<0.0001
Corrected Ca/P Ratio**	-	4.57 (2.38-12.16)*°	3.84 (3.33-8.33)^	2.63 (1.99-3.98)	<0.0001

*[footnote to Table 1]: PHPT: primary hyperparathyroidism, HypoP: hypophosphatemia, Ca: serum calcium; P: serum phosphorus; Ca/P: serum calcium to phosphorus ratio; **available in 124 PHPT patients (79.3%), 299 HypoP patients (97.7%) and 119 controls (79.3%). * PHPT vs Controls: p<0.0001; ° PHPT vs HypoP: p<0.0001; ^ HypoP vs Controls: p<0.0001; # HypoP vs Controls: p=0.001; § PHPT vs Controls: p=0.002*

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table 2. Diagnostic value of several parameters for the identification of disorders of Ca-P metabolism (PHPT and HypoP) in the entire cohort.

Values are expressed as percentage.

	Cut-off	Sensitivity	Specificity	PPV	NPV	Accuracy
Ca/P	3.56 (2.75 SI)	93.0	92.7	97.5	81.3	92.9
Corrected Ca/P Ratio	3.47 (2.68 SI)	93.4	93.2	98.0	79.7	93.3
Serum PTH (pg/mL)	88.0	32.7	100	100	33.6	49.8
Serum Ca (mg/dL)	10.5 (2.63 SI)	25.5	100	100	30.4	43.2
Serum corrected Ca (mg/dL)	10.5 (2.63 SI)	20.3	99.2	98.9	25.9	37.6
Serum P (mg/dL)	2.5 (0.81 SI)	82.2	100	100	64.9	86.6
Combined Ca/P and/or serum Ca*	3.56/10.5	95.2	92.7	97.5	86.3	94.6

*[footnote to Table 2]: PHPT: primary hyperparathyroidism; HypoP: hypophosphatemia; Ca: serum calcium; P: serum phosphorus; Ca/P: serum calcium to phosphorus ratio (Ca and P measured in mg/dL); PTH: serum parathyroid hormone (measured in pg/mL); SI: International System of Units (Ca and P are measured in mmol/L); Sensitivity: number of true positives divided by the number of true positives plus the number of false negatives; Specificity: number of true negatives divided by the number of true negatives plus the number of false positives; PPV: Positive predictive value: number of true positives divided by the number of true positives plus the number of false positives; NPV: negative predictive value: number of true negatives divided by the number of true negatives plus the number of false negatives. Accuracy: number of true positives plus the number of true negatives divided by the number of true positives plus the number of true negatives plus the number of false positives plus the number of false negatives. *Combined Ca/P and/or serum Ca was considered positive when at least one of the two biochemical parameters was above the cut-off.*

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table 3. Diagnostic value of several parameters for the diagnosis of PHPT among patients with Ca/P above 3.56. Values are expressed as percentage.

	Cut-off	Sensitivity	Specificity	PPV	NPV	Accuracy
Serum PTH (pg/mL)	80.5	90.9	90.9	80.9	96.0	90.9
Serum Ca (mg/dL)	10.3 (2.6 SI)	92.6	98.7	96.6	97.1	96.7
Serum corrected Ca (mg/dL)	9.6 (2.4 SI)	100	99.7	99.0	100	99.8
Serum P (mg/dL)	2.5 (0.8 SI)	57.0	0	18.5	0	16.3

[footnote to Table 3]: PHPT: primary hyperparathyroidism; HypoP: hypophosphatemia; PTH: serum parathyroid hormone (measured in pg/mL); Ca: serum calcium; P: serum phosphorus (Ca and P measured in mg/dL); SI: International System of Units (Ca and P are measured in mmol/L); Sensitivity: number of true positives divided by the number of true positives plus the number of false negatives; Specificity: number of true negatives divided by the number of true negatives plus the number of false positives; PPV: Positive predictive value: number of true positives divided by the number of true positives plus the number of false positives; NPV: negative predictive value: number of true negatives divided by the number of true negatives plus the number of false negatives. Accuracy: number of true positives plus the number of true negatives divided by the number of true positives plus the number of true negatives plus the number of false positives plus the number of false negatives.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65



[Click here to view linked References](#)

1
2
3
4
5
6
7 **RELIABILITY OF CALCIUM TO PHOSPHORUS (Ca/P) RATIO AS A NEW,**
8 **ACCURATE AND INEXPENSIVE TOOL IN THE DIAGNOSIS OF SOME Ca-P**
9 **DISORDERS**

10
11
12 Bruno Madeo, M.D., Ph.D.¹, Sara De Vincentis, M.D.^{1,2}, Elda Kara, M.D.^{2,3}, Fabio Vescini, M.D.,
13
14 Ph.D.³, Tommaso Trenti, M.D.⁴, Giovanni Guaraldi, M.D., Ph.D.⁵, Vincenzo Rochira M.D., Ph.D.^{1,2}
15
16

17
18 ¹Unit of Endocrinology, Department of Medical Specialties, Azienda Ospedaliero-Universitaria of
19
20 Modena, Modena, Italy. ²Unit of Endocrinology, Department of Biomedical, Metabolic and Neural
21
22 Sciences, University of Modena and Reggio Emilia, Modena, Italy. ³Endocrinology and
23
24 Metabolism Unit, University Hospital of Udine, Udine, Italy. ⁴Department of Laboratory Medicine
25
26 and Pathological Anatomy, Azienda USL of Modena, Modena, Italy. ⁵Multidisciplinary Metabolic
27
28 Clinic, Unit of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy.

29 **Corresponding author:**

30
31 Bruno Madeo – Unit of Endocrinology, Department of Medical Specialties, Azienda Ospedaliero-
32
33 Universitaria di Modena, Ospedale Civile di Baggiovara, Modena, Italy

34 Via Giardini, 1355 – 41126 MODENA, Italy

35
36 Phone: +390593961800 Fax: +390593961335 e-mail: bruno.madeo@unimore.it
37
38
39

40 **ORCID of the Authors:**

41
42 Bruno Madeo: 0000-0003-2881-982X

43
44 Sara De Vincentis: 0000-0002-9582-5683

45
46 Fabio Vescini: 0000-0003-1892-9785

47
48 Giovanni Guaraldi: 0000-0002-5724-3914

49
50 Vincenzo Rochira: 0000-0001-8169-0696

51 **Acknowledgments:** None.
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Formatted: English (United States)

Formatted: English (United States)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Abstract

Purpose: The serum calcium/phosphorus (Ca/P) ratio is an accurate tool to differentiate patients with primary hyperparathyroidism (PHPT) from healthy subjects. However, other disorders of the Ca-P metabolism might impair the Ca/P ratio, such as hypophosphatemia (HypoP) not PHPT-related. The aim of this study is to ~~validate-examine the diagnostic value~~~~the accuracy~~ of Ca/P ratio in the diagnosis of ~~Ca-P metabolism disorders, particularly~~ PHPT and HypoP not PHPT-related.

Methods: Single-center, retrospective, case-control study, including 150 patients with PHPT and 306 patients with HypoP, compared with 150 controls. HypoP patients were enrolled among HIV-infected patients by selecting those with Fanconi-like syndrome due to antiretroviral treatment.

~~Parameters which were measured were serum Ca, P, parathyroid hormone (PTH), 25-OH vitamin D, albumin and creatinine)~~~~Main outcomes: serum Ca, P, parathyroid hormone (PTH), 25-OH vitamin D, albumin and creatinine.~~

Results: The Ca/P ratio was significantly higher in PHPT and HypoP patients, compared to controls ($p < 0.0001$). At receiver operator characteristic (ROC) curve analysis, the cut-off of 3.56 (2.75 SI) for Ca/P ratio was able to identify patients with PHPT and HypoP (sensitivity 95%; specificity 93%). Among patients with Ca/P ratio above 3.56, the thresholds of 10.3 mg/dL (2.6 mmol/L) for serum Ca (sensitivity 93%; specificity 98%) and 80.5 pg/mL for PTH (sensitivity 91%; specificity 91%) were defined for the specific diagnosis of PHPT.

Conclusions: The Ca/P ratio above 3.56 (2.75 SI) is a highly accurate tool to identify PHPT and HypoP not PHPT-related patients. Thanks to its simplicity, this index can be proposed as a screening and first-line examination in the diagnostic work-up when a disorder of Ca-P metabolism is suspected or should be ruled out.

Key words: Calcium-Phosphorus metabolism, hyperparathyroidism, hypophosphatemia, screening

1
2
3
4
5
6
7
8 **Introduction**

9 The calcium to phosphorus (Ca/P) ratio has been recently proposed for the first time as a
10 simple and accurate tool to discriminate patients with primary hyperparathyroidism (PHPT) from
11 healthy subjects. The reliability of this index is based on the fact that Ca and P homeostasis are
12 closely regulated and their serum concentration is inversely correlated [1-3]. The diagnosis of
13 PHPT is traditionally based on increased serum Ca and intact parathyroid hormone (PTH) levels [4,
14 5], in association with slight or mild hypophosphatemia (HypoP) [5, 6]. However, the biochemical
15 profile of PHPT is not always so evident, making the diagnosis of PHPT challenging. For this
16 reason, the serum Ca/P ratio could help in the diagnostic workup of PHPT, especially in
17 asymptomatic or normocalcemic patients [3].

18
19
20
21
22
23
24
25
26 Nevertheless, although PHPT is the most common cause of hypercalcemia [6, 7], other
27 disorders of the Ca-P metabolism might impair the Ca/P ratio. For example, a condition of HypoP
28 not due to PHPT should be considered.

29
30
31 HypoP is a rare disease [8] that may occur by several mechanisms [9], including internal
32 redistribution (eg, malnutrition, sepsis) or increased urinary excretion (eg, X-linked
33 hypophosphatemic rickets, Fanconi syndrome) [10, 11]. A phosphate wasting disorder is also
34 frequently observed in patients with Human Immunodeficiency Virus (HIV)-infection with ongoing
35 combination antiretroviral therapy (cART) [12, 13]. In particular, among antiretroviral drugs, the
36 use of tenofovir has been correlated with mild to severe reduced serum hypophosphatemia,
37 through a renal tubular dysfunction and chronic increased phosphaturia, resulting in a Fanconi-like
38 syndrome [12-14].

39
40
41
42
43
44
45 In our previous study, the lack of a group of patients with HypoP limited the validation of
46 serum Ca/P ratio for the differential diagnosis between PHPT and other causes of altered Ca/P
47 ratio [3]. For example, tenofovir-related hypophosphatemia represents a mono-factorial
48 hypophosphatemia, making HIV-infected patients with HypoP a uniform cohort to compare with
49 PHPT patients.

1
2
3
4
5
6
7 The aim of the study is to evaluate the accuracy and diagnostic value of Ca/P in the diagnosis
8 of PHPT and HypoP related to Fanconi-like syndrome and to investigate if this index can be used
9 for differential diagnosis. ~~The aim of this study is to validate the accuracy and diagnostic value of~~
10 ~~Ca/P ratio in the diagnosis of Ca and P metabolism disorders such as PHPT and HypoP.~~
11
12
13
14
15

16 17 18 **Subjects and Methods**

19 *Study Design*

20 A single-centre, retrospective, case-control study was carried out.

21
22 The group of cases with ascertained diseases of Ca-P metabolism was composed by two
23 subgroups: patients with a certain diagnosis of PHPT and HIV-infected patients with HypoP.
24 Controls consisted of subjects without any disorder of Ca-P metabolism. This trial was registered in
25 ClinicalTrials.gov (Identifier: NCT03603444).
26
27
28
29
30

31 *Subjects*

32
33 A total of 150 patients followed at the Unit of Endocrinology of Modena with a diagnosis of
34 PHPT from 2005 to January 2018 were included in the first case group (Table 1). For the other
35 group of cases, 306 subjects with a certain diagnosis of drug-induced HypoP with reduced serum P
36 according to the lower limit of the normal range of our laboratory (2.5 mg/dL), but normal serum
37 Ca, were enrolled among HIV-infected patients on cART treatment from the large Modena cohort
38 that belongs to Modena HIV Metabolic Clinic (MHMC), from 2004 to 2017. In this tertiary care
39 teaching Hospital in Northern Italy, all individuals are screened by a multidisciplinary team for
40 immune-metabolic disorders, antiretroviral-associated toxicities, HIV-associated non-infectious
41 endocrine co-morbidities, geriatric syndromes and disabilities [15]. In particular, Ca, P, PTH and
42 vitamin D are routinely checked at baseline in order to exclude Ca metabolism disorders related to
43 osteoporosis or drug toxicity. By considering the low prevalence of hypophosphatemia in the
44
45
46
47
48
49
50
51
52
53
54

1
2
3
4
5
6
7 general population and the availability of a easily-accessible large database, we chose to investigate
8 the tenofovir-related hypophosphatemia since it allowed us to select quickly a large sample of
9 patients with hypophosphatemia and to have a homogeneous mono-factorial disease, such as
10 tenofovir-related hypophosphatemia, to compare with PHPT. Tenofovir-related hypophosphatemia,
11 however, should be considered highly representative of all other types of hypophosphatemia at least
12 for the aim of this study since it leads to the same changes in serum such as other types of
13 hypophosphatemia.

14
15
16
17
18
19
20 As a control group, we retrospectively selected 150 patients who attended the Unit of
21 Endocrinology of Modena in the same time period, presenting serum PTH, Ca and P within the
22 normal range. In particular, 43 (28.7%) were healthy subjects, 30 (20.0%) were male hypogonadal
23 patients with documented normal serum testosterone during testosterone replacement therapy, 27
24 (18.0%) had a pituitary disease (non-functioning pituitary adenoma or empty sella with normal
25 pituitary function), 17 (11.3%) had a non-functioning adrenocortical adenoma, 33 (22.0%) had a
26 thyroid disorder (history of thyroidectomy, chronic thyroiditis or nodular goiter).

27
28
29
30
31
32
33 _____ The following parameters were needed for the inclusion in each group: age, gender, serum Ca,
34 P, PTH, 25-OH vitamin D and creatinine (Table 1).

35
36 Exclusion criteria for both cases and controls were: age younger than 18 or older than 90 years;
37 severe renal and liver diseases (i.e. glomerular filtration rate (GFR) <30 mL/min);
38 hyperparathyroidism secondary to Vitamin D deficiency; history of parathyroidectomy, even if the
39 parathyroid disorder was considered in remission; active metabolic bone disease (e.g. Paget's
40 disease of the bone, osteomalacia, rickets, etc); any type of cancer; malnutrition; severe obesity
41 (BMI > 40 kg/m²); a history of gastrointestinal malabsorption; sarcoidosis; hypercortisolism,
42 diabetes insipidus, hyperthyroidism, hypoparathyroidism and pseudohypoparathyroidism; familial
43 hypocalciuric hypercalcemia (FHH); treatment with steroids, calcium and/or active forms of
44 vitamin D (calcitriol, ergocalciferol, etc), thiazides, phosphate binders, lithium, cinacalcet,
45 bisphosphonates, and denosumab.

1
2
3
4
5
6
7
8 The characteristics of patients and controls are summarized in Table 1.
9

10
11 *Laboratory analyses*

12 Serum Ca and P were detected using Beckman Coulter AU 680 (Beckman Coulter Italy,
13 Cassina de' Pecchi, Milan, Italy) device by the colorimetric photometric methods based on
14 Arsenazo III and molybdate, respectively. For both sexes, the normal reference ranges for serum Ca
15 and P were 8.5-10.5 mg/dL and 2.5-5.1 mg/dL, respectively.
16
17

18
19 Serum Intact PTH was determined by two house-different chemiluminescence assays: a
20 DiaSorin Liaison (DiaSorin S.p.A., Saluggia, Vercelli, Italy) from January 2005 to June 2010 and a
21 Beckman Coulter UniCel DxI 600 Synchron Access (Beckman Coulter Italy, Cassina de' Pecchi,
22 Milan, Italy) from June 2010 to January 2018. The normal reference range for serum PTH was 15-
23 88 ng/L, with an intra-assay variability coefficient of 5%.
24
25

26
27 Serum 25OH-Vitamin D was measured by chemiluminescence with the LIASON® XL
28 1,25OH-Vitamin D assay (DiaSorin, Stillwater, MN). Normal reference range is 30-100 ng/mL and
29 the intra- and inter-assay variability coefficient was <10%.
30
31

32
33 Plasma albumin-adjusted corrected Ca (corrected Ca) was calculated to account for falsely low
34 serum calcium values due to hypoalbuminemia. We applied the following formula to all patients for
35 which serum albumin was available in the record chart: corrected total calcium (mg/dL) = total
36 serum calcium (mg/dL) + 0.8*[4 – serum albumin (g/L)] [5, 16].
37
38
39

40
41
42
43 *Ethics*

44
45 Consent has been obtained from each patient or subject after full explanation of the purpose
46 and nature of all procedures used.
47

48
49 The Institutional Review Board of Azienda Ospedaliero-Universitaria of Modena approved the
50 study (Protocol n. 0032443/15).
51
52

1
2
3
4
5
6
7
8 **Statistical analysis**

9 All data are shown as median and minimum-maximum. Comparisons among groups were
10 performed by the nonparametric Mann-Whitney *U* and Kruskal-Wallis tests, followed by the
11 Dunn's post hoc test, since variables were not normally distributed at Kolmogorov-Smirnov test.
12
13

14 The diagnostic accuracy of Ca/P was investigated using receiver operator characteristic (ROC)
15 curve in order to define cut-off points that better identify affected patients according to their
16 biochemical profile. ROC cut-offs were calculated by the Youden's index through the identification
17 of the best pair of sensitivity and specificity.
18
19

20 Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and
21 accuracy were evaluated.
22
23

24 Statistical analyses were performed using the Statistical Package for the Social Sciences'
25 (SPSS) software for Windows (version 25.0; SPSS Inc, Chicago, IL). For all comparisons, $p < 0.05$
26 was considered statistically significant.
27
28
29
30

31
32
33 **Results**

34 Age, sex and biochemical parameters of each group are summarized in Table 1.

35 Serum Ca was significantly higher in PHPT patients than either HypoP patients or controls
36 ($p < 0.0001$) (Table 1). As expected, even serum PTH was higher in PHPT group than others
37 ($p < 0.0001$) (Table 1).
38
39

40 Conversely, serum P was significantly lower in HypoP patients than PHPT patients and
41 controls ($p < 0.0001$) (Table 1).
42
43

44 The Ca/P ratio was significantly lower in controls compared to both PHPT ($p < 0.0001$) and
45 HypoP patients ($p < 0.0001$), but it did not significantly differ among HypoP and PHPT groups
46 ($p = 0.075$) (Table 1).
47
48

49 Serum albumin, necessary for the calculation of corrected Ca, was available in 124 PHPT
50 patients (79.3%), 299 HypoP patients (97.7%) and 119 controls (79.3%) (Table 1). Similarly, to
51
52
53

1
2
3
4
5
6
7 serum Ca, even serum corrected Ca was higher in PHPT patients than controls (p<0.0001) and
8 HypoP patients (p<0.0001) (Table 1).

9
10
11 Serum creatinine and vitamin D did not differ between controls and PHPT patients, but they
12 were it was significantly higher in HypoP group (p<0.0001) (Table 1). In particular, 57 controls
13 (38.3%), 69 PHPT patients (50.7%) and 70 HypoP patients (23.9%) had vitamin D deficiency with
14 serum levels of 25-OH vitamin D below 20 ng/mL.

15
16
17 Considering renal function, serum creatinine did not differ comparing controls to PHPT group,
18 but it was higher in HypoP group (<0.0001) (Table 1). The GFR was between 30 and 60 mL/min in
19 8 controls (6.2%), 19 PHPT (12.8%) and 15 HypoP (4.9%) patients; all other subjects had a GFR
20 greater than 60 mL/min.

21
22
23
24
25 In addition, HIV-infected patients and controls were mostly male patients, while PHPT were
26 predominantly female (Table 1). HIV-infected patients were significantly younger than PHPT
27 patients and controls (p<0.0001) (Table 1).

28
29
30 Among PHPT patients, 38 (25.3%) were normocalcemic, while 112 (74.7%) had serum Ca
31 above the normal range.

32
33
34
35 Table 2 shows the diagnostic values of conventional parameters used to define a condition of
36 altered Ca-P metabolism, including either PHPT or HypoP. The Ca/P threshold of 3.56 (2.75 SI),
37 obtained by ROC curve analysis, was identified as the best pair of sensitivity (93%) and specificity
38 (92.7%) (Table 2, Figure 1a). In particular, by using the Ca/P ratio with a cut-off of 3.56, 424 out of
39 the 456 HypoP and PHPT patients were correctly identified as patients with Ca-P metabolism
40 disorder, while only 11 out of the 150 controls were falsely classified as having a disorder of Ca-P
41 metabolism (Figure 2). When serum albumin was available, the use of serum corrected Ca/P ratio
42 with a cut-off of 3.47 (2.68 SI) had a diagnostic power (sensitivity 93.4%, specificity 93.2%)
43 similar to that of Ca/P (Table 2). Accordingly, PPV, NPV and accuracy of both Ca/P and corrected
44 Ca/P were the best ones compared to the diagnostic values of PTH, serum Ca, corrected Ca and P
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7 (Table 2). As expected, either serum Ca or PTH that were used as inclusion criteria for controls, act
8 as confounders for the diagnostic performance (Table 2).
9

10
11 The combined use of Ca/P and serum Ca (which was considered positive when at least one of
12 the two biochemical parameters was above the respective cut-offs) had the best sensitivity (95.2%)
13 and specificity (92.7%) together with the best PPV, NPV and accuracy, all these parameters
14 performing better than Ca/P alone to identify patients with impaired Ca-P metabolism (Table 2).
15

16
17 The statistical analysis performed by considering only normocalcemic patients from the PHPT
18 cohort confirmed that 3.56 of Ca/P ratio was reliable to identify the cases (normocalcemic PHPT
19 and HypoP) from controls. However, no valid cut-off was found to differentiate normocalcemic
20 PHPT from HypoP patients.
21

22
23 Similarly, ROC curve analysis performed for patients with sufficient vitamin D and for patients
24 with vitamin D insufficiency showed the same cut-off (Ca/P 3.56) with similar specificity and
25 sensitivity. The same results were obtained comparing the ROC curves of patients with GFR 30-60
26 ml/min with those with GFR >60 ml/min.
27

28
29 Overall, by considering all patients with Ca-P metabolism disorder (PHPT and HypoP) with
30 Ca/P above 3.56, the use of serum Ca and/or serum PTH alone had the best diagnostic value in
31 discriminating PHPT from HypoP patients, as expected (Table 3, Figure 1b). In particular, the
32 thresholds of 10.3 mg/dL (2.6 mmol/L) for serum Ca (sensitivity 92.6%; specificity 98.7%) and of
33 80.5 pg/mL for PTH (sensitivity 90.9%; specificity 90.9%) were defined for the specific diagnosis
34 of PHPT (Table 3, Figure 1b). Similarly, for those patients whose albumin was measured, corrected
35 Ca had very high diagnostic power for the threshold of 9.85 mg/dL (sensitivity 100%, specificity
36 99.7%) (Table 3).
37

38
39 On the other hand, it was not possible to identify any useful cut-off for serum P in order to
40 discriminate PHPT from HypoP (Table 3).
41

42 Discussion

1
2
3
4
5
6
7
8 This study shows that serum Ca/P ratio has a great diagnostic power in identifying patients
9 with PHPT and patients with HypoP not PHPT-related. In particular, a Ca/P value above 3.56 (with
10 Ca and P measured in mg/dL) results to be an accurate, highly sensitive and highly specific tool to
11 define a condition of impaired Ca-P metabolism due to PHPT or HypoP not PHPT-related. More
12 importantly, both sensitivity and accuracy further increases if serum Ca and Ca/P are used in
13 combination (Table 2).
14
15
16
17

18 This is in line with our previous results, since the accuracy of Ca/P to diagnose or rule out a
19 condition of PHPT remained unaltered after adding patients with HypoP [3]. In addition to PHPT
20 group, the inclusion of HypoP patients allowed us to investigate the accuracy of Ca/P in the
21 differential diagnosis of other Ca-P metabolism disorders, such as HypoP not PHPT-related.
22 Unfortunately, we did not find any valid cut-off of Ca/P ratio useful to discriminate patients with
23 ~~PHPT from those with~~ HypoP not PHPT-related from those with PHPT, either normocalcemic or
24 hypercalcemic. Thus, up to now, we can conclude that this index is not useful to differentiate PHPT
25 from HypoP among disorders of Ca-P metabolism.
26
27
28
29
30
31
32

33 At the same time, our results show that the use of serum Ca alone with a cut-off of 10.3 mg/dL
34 allows identifying patients with PHPT among all patients with Ca/P ratio above 3.56. In this
35 perspective, we recommend measuring serum Ca and P as first step in the screening of Ca-P
36 metabolism disorders (Figure 3). Serum Ca allows to define a condition of PHPT or HypoP due to
37 other causes, once the calculated Ca/P ratio is found above 3.56 (Figure 3). Accordingly, PHPT or
38 HypoP not related to PHPT should be highly considered when serum Ca is above or below 10.3
39 mg/dL, respectively (Figure 3). As a consequence and in contrast to the current guidelines on the
40 management of PHPT [4], not only Ca and ~~PTH~~, but also P, are useful for identifying patients
41 with PHPT. For this reason, we recommend including serum P in the clinical work-up for the
42 diagnosis of PHPT. On the other hand, this study further demonstrates that serum P alone is
43 unreliable in the diagnosis of PHPT, in accordance with all previous studies that evaluated this
44 parameter alone and never in combination with serum Ca [17-20]. In the literature, there is no
45
46
47
48
49
50
51
52
53
54

1
2
3
4
5
6
7
8 agreement about the use of serum P as first-step examination in the diagnostic work-up of bone
9 mineral diseases. Current clinical guidelines do not actually recommend to measure serum P for the
10 diagnosis of PHPT [4] and for the management of nephrolithiasis [21-23]. On the contrary, serum P
11 is included among first tier investigations for urolithiasis by a recent consensus statement [24] and
12 for the management of osteoporosis by several Societies [25-30]. Again, we recommend measuring
13 serum P together with serum total Ca allowing to calculate Ca/P as screening of Ca-P metabolism
14 disorders, especially in the above-mentioned clinical settings, while serum PTH is not strictly
15 needed as first-line biochemical investigation to rule out PHPT (Figure 3).
16
17
18
19
20
21

22 In the clinical real-life, the measurement of serum Ca and serum P may be sufficient as first
23 investigation for the diagnosis of PHPT that is one of the most frequent disorders of Ca-P
24 metabolism [6, 7]. In addition to their worldwide availability and extreme simplicity, the use of
25 serum Ca and P may avoid further outgoings and clinical complications due to a delayed diagnosis
26 of PHPT, occurring in a relevant percentage (about 40%) of cases [4, 31-34].
27
28
29
30

31 The retrospective design represents the main limit of this study, but it assures a correct
32 assignment to control or case (either PHPT or HypoP) groups. Another limit is represented by the
33 lack of age- and gender-matching between patients and controls. Furthermore, vitamin D
34 insufficiency and slight impairment of GFR seem to not influence the accuracy of Ca/P index.
35
36
37

38 In conclusion, this study further validates the serum Ca/P ratio above 3.56 (2.75 SI) as a highly
39 accurate tool to identify patients with PHPT and HypoP not PHPT-related. Thanks to its
40 extraordinary simplicity, together with the favourable cost-effectiveness, this index can be proposed
41 as a screening and first-line examination in the diagnostic work-up when a disorder of Ca-P
42 metabolism is suspected or should be ruled out, such as in patients with osteoporosis or
43 nephrolithiasis. Moreover, both sensitivity and accuracy further increases when Ca/P ratio is taken
44 in combination with serum total Ca. The use of a simple index, such as Ca/P, might be particularly
45 useful especially in laboratory/medical settings relying on limited resource, in which second- or
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7 third-generation assays for PTH are not available. Furthermore, the timely diagnosis of PHPT is
8 useful for preventing the development of PHPT-related comorbidities.
9

10
11 Finally, prospective and multi-centre studies on larger sample size will be needed to confirm
12 and validate our findings for PHPT and HypoP patients. Moreover, future studies may be performed
13 to extent the application of Ca/P to diagnose other disorders of Ca-P metabolism, such as
14 hypoparathyroidism, pseudohypoparathyroidism and secondary hyperparathyroidism
15
16
17

18 19 20 **Declaration of interest**

21
22 The authors declare that they have no conflict of interest.
23
24

25 26 **Funding**

27 This research did not receive any specific grant from any funding agency in the public, commercial
28 or not-for-profit sector.
29
30

31 32 33 **Authors contributions**

34 B. Madeo is the Principal Investigator and conceived the study, analysed the data, provided data
35 interpretation and wrote the manuscript. S. De Vincentis collected and analyzed the data, and wrote
36 the manuscript. E. Kara collected clinical and biochemical data. F. Vescini contributed to conceive
37 the study. T. Trenti provided data about laboratory assays. G. Guaraldi provided clinical and
38 biochemical data about HypoP patients. V. Rochira conceived the study, analysed the data,
39 provided data interpretation and wrote the manuscript. All authors approved the final version of the
40 manuscript and fully contributed to its final version.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8 **References**

- 9
10 1. Shaker JL, Deftos L (2000) Calcium and Phosphate Homeostasis. In De Groot LJ, Chrousos G,
11 Dungan K, et al. (eds) Endotext. MDText.com, Inc., South Dartmouth (MA)
12
13 2. Peacock M (2010) Calcium metabolism in health and disease. Clin J Am Soc Nephrol 5 Suppl
14 1:S23-30
15
16 3. Madeo B, Kara E, Cioni K, Vezzani S, Trenti T, Santi D, Simoni M, Rochira V (2018) Serum
17 Calcium to Phosphorous (Ca/P) Ratio Is a Simple, Inexpensive, and Accurate Tool in the
18 Diagnosis of Primary Hyperparathyroidism. JBMR Plus 2:109-117
19
20 4. Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, Potts JT, Jr.
21 (2014) Guidelines for the management of asymptomatic primary hyperparathyroidism:
22 summary statement from the Fourth International Workshop. J Clin Endocrinol Metab
23 99:3561-3569
24
25 5. Marcocci C, Cetani F (2011) Clinical practice. Primary hyperparathyroidism. The New
26 England journal of medicine 365:2389-2397
27
28 6. Fraser WD (2009) Hyperparathyroidism. Lancet 374:145-158
29
30 7. Griebeler ML, Kearns AE, Ryu E, Hathcock MA, Melton LJ, 3rd, Wermers RA (2015) Secular
31 trends in the incidence of primary hyperparathyroidism over five decades (1965-2010). Bone
32 73:1-7
33
34 8. Christov M, Juppner H (2018) Phosphate homeostasis disorders. Best Pract Res Clin
35 Endocrinol Metab 32:685-706
36
37 9. Boland JM, Tebben PJ, Folpe AL (2018) Phosphaturic mesenchymal tumors: what an
38 endocrinologist should know. J Endocrinol Invest 41:1173-1184
39
40 10. Gaasbeek A, Meinders AE (2005) Hypophosphatemia: an update on its etiology and treatment.
41 Am J Med 118:1094-1101
42
43 11. Marcucci G, Masi L, Ferrari S, Haffner D, Javaid MK, Kamenicky P, Reginster JY, Rizzoli R,
44 Brandi ML (2018) Phosphate wasting disorders in adults. Osteoporos Int
45
46
47
48
49
50
51
52
53
54

Formatted: Italian (Italy)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

12. Casado JL, Santiuste C, Vazquez M, Banon S, Rosillo M, Gomez A, Perez-Elias MJ, Caballero C, Rey JM, Moreno S (2016) Bone mineral density decline according to renal tubular dysfunction and phosphaturia in tenofovir-exposed HIV-infected patients. *Aids* 30:1423-1431

13. Bagnis CI, Karie S, Deray G, Essig M (2009) Hypophosphataemia: an easy strategy for diagnosis and treatment in HIV patients. *Antivir Ther* 14:481-488

14. Labarga P, Barreiro P, Martin-Carbonero L, et al. (2009) Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. *Aids* 23:689-696

15. Rochira V, Zirilli L, Orlando G, Santi D, Brigante G, Diazzi C, Carli F, Carani C, Guaraldi G (2011) Premature decline of serum total testosterone in HIV-infected men in the HAART-era. *PLoS One* 6:e28512

16. Smith JD, Wilson S, Schneider HG (2018) Misclassification of Calcium Status Based on Albumin-Adjusted Calcium: Studies in a Tertiary Hospital Setting. *Clin Chem* 64:1713-1722

17. Boyd JC, Ladenson JH (1984) Value of laboratory tests in the differential diagnosis of hypercalcemia. *Am J Med* 77:863-872

18. Avioli LV (1968) The diagnosis of primary hyperparathyroidism. *Med Clin North Am* 52:451-462

19. Strott CA, Nugent CA (1968) Laboratory tests in the diagnosis of hyperparathyroidism in hypercalcemic patients. *Ann Intern Med* 68:188-202

20. Reiss E (1970) Primary hyperparathyroidism: a simplified approach to diagnosis. *Med Clin North Am* 54:131-139

21. Turk C, Petrik A, Sarica K, Seitz C, Skolarikos A, Straub M, Knoll T (2016) EAU Guidelines on Diagnosis and Conservative Management of Urolithiasis. *Eur Urol* 69:468-474

22. Pearle MS, Goldfarb DS, Assimos DG, et al. (2014) Medical management of kidney stones: AUA guideline. *J Urol* 192:316-324

23. Morgan MS, Pearle MS (2016) Medical management of renal stones. *Bmj* 352:i52

Formatted: Italian (Italy)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

24. Gambaro G, Croppi E, Coe F, et al. (2016) Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement. *J Nephrol* 29:715-734

25. Camacho PM, Petak SM, Binkley N, et al. (2016) AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016. *Endocr Pract* 22:1-42

26. Rossini M, Adami S, Bertoldo F, et al. (2016) Guidelines for the diagnosis, prevention and management of osteoporosis. *Reumatismo* 68:1-39

27. Nuti R, Brandi ML, Checchia G, et al. (2018) Guidelines for the management of osteoporosis and fragility fractures. *Intern Emerg Med*

28. Rochira V, Antonio L, Vanderschueren D (2018) EAA clinical guideline on management of bone health in the andrological outpatient clinic. *Andrology* 6:272-285

29. Vescini F, Attanasio R, Balestrieri A, et al. (2016) Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis. *J Endocrinol Invest* 39:807-834

30. Compston J, Bowring C, Cooper A, et al. (2013) Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. *Maturitas* 75:392-396

31. Chen G, Xue Y, Zhang Q, et al. (2015) Is Normocalcemic Primary Hyperparathyroidism Harmful or Harmless? *J Clin Endocrinol Metab* 100:2420-2424

32. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP (1999) A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. *N Engl J Med* 341:1249-1255

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

33. Lundstam K, Heck A, Mollerup C, et al. (2015) Effects of parathyroidectomy versus observation on the development of vertebral fractures in mild primary hyperparathyroidism. *J Clin Endocrinol Metab* 100:1359-1367

34. Eastell R, Brandi ML, Costa AG, D'Amour P, Shoback DM, Thakker RV (2014) Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. *J Clin Endocrinol Metab* 99:3570-3579

1
2
3
4
5
6
7
8 **Legends**

9 **Figure 1a.** ROC curve analysis for Ca/P together with cut-off, sensitivity, specificity, area under
10 the curve, standard error, and 95% confidence interval values. **Figure 1b.** ROC curve analysis for
11 Ca and PTH among PHPT and HypoP patients with Ca/P above 3.56 (2.75 SI), together with cut-
12 off, sensitivity, specificity, area under the curve, standard error, and 95% confidence interval
13 values.
14
15
16
17

18 *[footnote to Figure 1]: Ca/P: serum calcium/phosphorus ratio (Ca and P measured in mg/dL); SI:*
19 *International System of Units (Ca and P are measured in mmol/L); AUC: Area Under the Curve;*
20 *SE: Standard Error; CI: Confidence Interval. Ca: serum calcium (black line in Figure 1b); PTH:*
21 *serum parathyroid hormone (grey line in Figure 1b); PHPT: primary hyperparathyroidism;*
22 *HypoP: hypophosphemia.*
23
24
25
26
27

28
29 **Figure 2.** Distribution of serum Ca/P ratio and serum Ca of all patients according to the thresholds
30 of 3.56 for Ca/P ratio, to discriminate controls from PHPT and HypoP, and of 10.3 mg/dL for serum
31 Ca, to discriminate PHPT from HypoP in patients with Ca/P > 3.56.
32
33

34 *[footnote to Figure 2]: Ca/P: serum calcium to phosphorus ratio; Ca: serum calcium (Ca and P*
35 *measured in mg/dL); controls (marker: black diamonds); PHPT: primary hyperparathyroidism*
36 *(marker: light grey circles); HypoP: hypophosphatemia (marker: dark grey triangles).*
37
38
39
40
41

42 **Figure 3.** Usefulness of Ca/P in the diagnostic flow-chart for the screening and diagnosis of Ca-P
43 metabolism disorders.
44

45 *[footnote to Figure 3]: Ca: serum calcium; Ca/P: serum calcium/phosphorus ratio (Ca and P*
46 *measured in mg/dL); PHPT: primary hyperparathyroidism; HypoP: hypophosphatemia; SI:*
47 *International System of Units (Ca and P are measured in mmol/L)*
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table 1. Age, biochemical and hormonal differences between patients with PHPT, HypoP and controls. Measurements are expressed as median (minimum-maximum).

	Normal range	PHPT n=150	HypoP n=306	Controls n=150	p-value
Sex					
Females	-	113 (75.3%)	54 (17.6%)	64 (42.7%)	-
Males	-	37 (24.7%)	252 (82.4%)	86 (57.3%)	-
Age (yrs)	-	63.5 (23.7-90.0)*°	48.5 (27.4-77.0)^	57.1 (19.8-89.0)	<0.0001
Serum Ca (mg/dL)	8.5-10.5	10.9 (9.3-18.0)*°	9.4 (8.5-10.5)	9.4 (8.7-10.5)	<0.0001
Serum P (mg/dL)	2.5-5.1	2.5 (1.5-3.9)*°	2.3 (1.5-2.5)^	3.6 (2.5-4.9)	<0.0001
Ca/P	-	4.36 (2.38-12.00)*	4.07 (3.46-6.20)^	2.69 (2.02-4.08)	<0.0001
Serum PTH (pg/mL)	15-88	130.6 (49.9-1748.0)*°	42.4 (6.2-308.2)#	34.0 (14.0-88.0)	<0.0001
Serum 25-OH vitamin D (ng/mL)	30-100	19.7 (3.0-59.2)°	29.1 (4.0-100.0)^	22.7 (4.0-74.8)	<0.0001
Serum creatinine (mg/dL)	0.50-1.20	0.80 (0.50-2.58)°	0.91 (0.53-2.35)^	0.80 (0.55-1.70)	<0.0001
Serum albumin (g/dL)**	3.5-5.0	4.1 (2.6-5.0)§°	4.6 (3.4-5.6)^	4.3 (2.7-4.9)	<0.0001
Serum corrected Ca (mg/dL)**	-	10.9 (9.3-18.2)*°	8.8 (7.9-9.9)^	9.2 (8.6-10.7)	<0.0001
Corrected Ca/P Ratio**	-	4.57 (2.38-12.16)*°	3.84 (3.33-8.33)^	2.63 (1.99-3.98)	<0.0001

[footnote to Table 1]: PHPT: primary hyperparathyroidism, HypoP: hypophosphatemia, Ca: serum calcium; P: serum phosphorus; Ca/P: serum calcium to phosphorus ratio; **available in 124 PHPT patients (79.3%), 299 HypoP patients (97.7%) and 119 controls (79.3%). * PHPT vs Controls: $p < 0.0001$; ° PHPT vs HypoP: $p < 0.0001$; ^ HypoP vs Controls: $p < 0.0001$; # HypoP vs Controls: $p = 0.001$; § PHPT vs Controls: $p = 0.002$

Table 2. Diagnostic value of several parameters for the identification of disorders of Ca-P metabolism (PHPT and HypoP) in the entire cohort.

Values are expressed as percentage.

	Cut-off	Sensitivity	Specificity	PPV	NPV	Accuracy
Ca/P	3.56 (2.75 SI)	93.0	92.7	97.5	81.3	92.9
Corrected Ca/P Ratio	3.47 (2.68 SI)	93.4	93.2	98.0	79.7	93.3
Serum PTH (pg/mL)	88.0	32.7	100	100	33.6	49.8
Serum Ca (mg/dL)	10.5 (2.63 SI)	25.5	100	100	30.4	43.2
Serum corrected Ca (mg/dL)	10.5 (2.63 SI)	20.3	99.2	98.9	25.9	37.6
Serum P (mg/dL)	2.5 (0.81 SI)	82.2	100	100	64.9	86.6
Combined Ca/P and/or serum Ca*	3.56/10.5	95.2	92.7	97.5	86.3	94.6

*[footnote to Table 2]: PHPT: primary hyperparathyroidism; HypoP: hypophosphatemia; Ca: serum calcium; P: serum phosphorus; Ca/P: serum calcium to phosphorus ratio (Ca and P measured in mg/dL); PTH: serum parathyroid hormone (measured in pg/mL); SI: International System of Units (Ca and P are measured in mmol/L); Sensitivity: number of true positives divided by the number of true positives plus the number of false negatives; Specificity: number of true negatives divided by the number of true negatives plus the number of false positives; PPV: Positive predictive value: number of true positives divided by the number of true positives plus the number of false positives; NPV: negative predictive value: number of true negatives divided by the number of true negatives plus the number of false negatives. Accuracy: number of true positives plus the number of true negatives divided by the number of true positives plus the number of true negatives plus the number of false positives plus the number of false negatives. *Combined Ca/P and/or serum Ca was considered positive when at least one of the two biochemical parameters was above the cut-off.*


16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table 3. Diagnostic value of several parameters for the diagnosis of PHPT among patients with Ca/P above 3.56. Values are expressed as percentage.

	Cut-off	Sensitivity	Specificity	PPV	NPV	Accuracy
Serum PTH (pg/mL)	80.5	90.9	90.9	80.9	96.0	90.9
Serum Ca (mg/dL)	10.3 (2.6 SI)	92.6	98.7	96.6	97.1	96.7
Serum corrected Ca (mg/dL)	9.6 (2.4 SI)	100	99.7	99.0	100	99.8
Serum P (mg/dL)	2.5 (0.8 SI)	57.0	0	18.5	0	16.3

[footnote to Table 3]: PHPT: primary hyperparathyroidism; HypoP: hypophosphatemia; PTH: serum parathyroid hormone (measured in pg/mL); Ca: serum calcium; P: serum phosphorus (Ca and P measured in mg/dL); SI: International System of Units (Ca and P are measured in mmol/L); Sensitivity: number of true positives divided by the number of true positives plus the number of false negatives; Specificity: number of true negatives divided by the number of true negatives plus the number of false positives; PPV: Positive predictive value: number of true positives divided by the number of true positives plus the number of false positives; NPV: negative predictive value: number of true negatives divided by the number of true negatives plus the number of false negatives. Accuracy: number of true positives plus the number of true negatives divided by the number of true positives plus the number of true negatives plus the number of false positives plus the number of false negatives.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65







Figure 2. Distribution of serum Ca/P ratio and serum Ca of all patients according to the thresholds of 3.56 for Ca/P ratio, to discriminate controls from PHPT and HypoP, and




Figure 3. Usefulness of Ca/P in the diagnostic flow-chart for the screening and diagnosis of Ca-P metabolism disorders.

